With Biohaven's Nurtec ODT Off And Running, Focus Turns To What Is Next
Executive Summary
The oral CGRP inhibitor for migraine generated solid second quarter results as the company expanded to the prevention setting. Several new potential growth drivers are moving through the pipeline.
You may also be interested in...
Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters
The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.
AbbVie Ready To Leverage Migraine Franchise In Crowded Market
The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.
AstraZeneca's Ultomiris Disappoints In ALS, Setting Back Rare Disease Ambitions
AstraZeneca is discontinuing a Phase III trial of the long-acting complement inhibitor it gained via its Alexion acquisition in amyotrophic lateral sclerosis because of lack of efficacy in an interim analysis. Interest is now turning to antisense and cell therapy candidates from other companies that are in late-stage development for the condition.